Abstract
AbstractProdigiosin, a secondary metabolite red pigment produced by Serratia marcescens, has an interesting apoptotic efficacy against cancer cell lines with low or no toxicity on normal cells. HSP90α is known as a crucial and multimodal target in the treatment of TNBC. Our research attempts to assess the therapeutic potential of prodigiosin/PU-H71 combination on MDA-MB-231 cell line. The transcription and protein expression levels of different signalling pathways were assessed. Treatment of TNBC cells with both drugs resulted in a decrease of the number of adherent cells with apoptotic effects. Prodigiosin/PU-H71 combination increased the levels of caspases 3,8 and 9 and decreased the levels of mTOR expression. Additionally, there was a remarkable decrease of HSP90α transcription and expression levels upon treatment with combined therapy. Also, EGFR and VEGF expression levels decreased. This is the first study to show that prodigiosin/PU-H71 combination had potent cytotoxicity on MDA-MB-231 cells; proving to play a paramount role in interfering with key signalling pathways in TNBC. Interestingly, prodigiosin might be a potential anticancer agent to increase the sensitivity of TNBC cells to apoptosis. This study provides a new basis for upcoming studies to overcome drug resistance in TNBC cells.
Publisher
Springer Science and Business Media LLC
Reference124 articles.
1. What is Breast Cancer? American Cancer Society (2019). https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html.
2. Botesteanu, D.-A., Lipkowitz, S., Lee, J.-M. & Levy, D. Mathematical models of breast and ovarian cancers. Syst. Biol. Med. 8, 337–362 (2016).
3. Masoud, V. & Pagès, G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J. Clin. Oncol. 8, 120–134 (2017).
4. Blake, A. et al. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance. Sci. Rep. 7, 1–17 (2017).
5. Lebert, J., Lester, R., Powell, E., Seal, M. & Mccarthy, J. Advances in the systemic treatment of triple-negative breast cancer. Curr. Oncol. 25, S142–S150 (2018).
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献